Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.69 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | C5 | P01031 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102734 | 0.88 | HDAC8 (0.65) | NR1H4NOTUMRAB9AALDH1A1NPC1 | |
| SCHEMBL20721702 | 0.84 | MAPT (0.64) | NR1H4RAB9AALDH1A1NPC1KMT2A | |
| SCHEMBL1544685 | 0.84 | RXRA (0.60) | NR1H4NOTUMRAB9AALDH1A1NPC1 | |
| SCHEMBL27745862 | 0.83 | ALDH1A1 (0.65) | NR1H4NOTUMRAB9AALDH1A1NPC1 | |
| SCHEMBL562313 | 0.83 | ALDH1A1 (0.62) | NR1H4NOTUMRAB9AALDH1A1NPC1 | |
| SCHEMBL7974806 | 0.83 | NOTUM (0.57) | NR1H4NOTUMRAB9AALDH1A1NPC1 | |
| SCHEMBL7974803 | 0.81 | NOTUM (0.55) | NR1H4NOTUMRAB9AALDH1A1NPC1 | |
| SCHEMBL24073125 | 0.80 | NR1H4 (0.64) | NR1H4RAB9AALDH1A1NPC1KMT2A | |
| SCHEMBL9257912 | 0.80 | NR1H4 (0.61) | NR1H4RAB9AALDH1A1NPC1KMT2A | |
| SCHEMBL3518708 | 0.79 | NR1H4 (0.60) | NR1H4RAB9AALDH1A1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360138-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | UNIV VIRGINIA COMMONWEALTH (US) | 2024-10-31 | — | — | US | disclosed |
| EP-3538101-B1 | INHIBITORS OF CANCER AND/OR METASTASIS | UNIV VIRGINIA COMMONWEALTH (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11891399-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2024-02-06 | — | — | US | disclosed |
| US-11478457-B2 | Castration-resistant prostate cancer | NUTECH VENTURES (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210214365-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | Sanford Burnham Prebys Medical Discovery Institute | 2021-07-15 | — | — | US | disclosed |
| US-11008325-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008325-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3538101-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | Virginia Commonwealth University (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190263824-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | VIRGINIA COMMONWEALTH UNIVERSITY | 2019-08-29 | — | — | US | disclosed |
| WO-2018089967-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-7511050-B2 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007150025-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150025-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891399-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | SDCBP, SDC1, SDAD1 | NR1H4 2874/4885NOTUM 3934/4885RAB9A 261/4885 |
| US-20210214365-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | SDCBP, SDC1, SDAD1 | NR1H4 2874/4885NOTUM 3934/4885RAB9A 261/4885 |
| US-20190263824-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | SDCBP, SDC1, SDAD1 | NR1H4 2874/4885NOTUM 3934/4885RAB9A 261/4885 |
| US-11478457-B2 | Castration-resistant prostate cancer | UGDH, G6PD, DPYD | NR1H4 1620/4885NOTUM 1799/4885RAB9A 2689/4885 |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | HMGCR, LDLR, GPBAR1 | NR1H4 13/4885NOTUM 2009/4885RAB9A 2219/4885 |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | NR1H4 333/4885NOTUM 4460/4885RAB9A 928/4885 |
| US-20240360138-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | SDCBP, SDC1, SDC2 | NR1H4 2959/4885NOTUM 3706/4885RAB9A 244/4885 |
| US-11008325-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | SDCBP, SDC1, SDAD1 | NR1H4 2874/4885NOTUM 3934/4885RAB9A 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.